Authors:
Timothy E. Ritter, MD – Texas Digestive Disease Consultants, PA, Southlake, TX
Chris Fourment, MD – Texas Digestive Disease Consultants, PA, Southlake, TX;
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc., Sugar Land, TX
Thomas C. Hardin, PharmD, – Healix Infusion Therapy, Inc., Sugar Land, TX
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Inc., Sugar Land, TX
Long-Term Safety Analysis of Vedolizumab for Treatment of Crohn’s Disease and Ulcerative Colitis
